Despite previous circulation of the highly transmissible and antibody evasive BA.2.75, BQ.1, XBB.1 and XBB.1.5 lineages, the share of infections caused by the SARS-CoV-2 lineage XBB.1.16 has gradually increased in Ind...Despite previous circulation of the highly transmissible and antibody evasive BA.2.75, BQ.1, XBB.1 and XBB.1.5 lineages, the share of infections caused by the SARS-CoV-2 lineage XBB.1.16 has gradually increased in India in early 2023, resulting in XBB.1.16 being the dominating SARS-CoV-2 lineage in India today. Since a similar trend may also take place in other countries and information on the biological properties of the XBB.1.16 lineage is scarce, we conducted a rapid assessment of the SARS-CoV-2 XBB.1.16 lineage with respect to its ability to enter cells and evade neutralisation by antibodies.展开更多
The emergence of SARS-CoV-2 variants threatens efforts to control the COVID-19 pandemic.At present,the global spread of the Delta(B.1.617.2)variant is responsible for a rapid increase in COVID-19 cases and hospitaliza...The emergence of SARS-CoV-2 variants threatens efforts to control the COVID-19 pandemic.At present,the global spread of the Delta(B.1.617.2)variant is responsible for a rapid increase in COVID-19 cases and hospitalizations in many countries.The variant evades neutralizing antibodies and is believed to be more transmissible and pathogenic[1,2,3,4].展开更多
The COVID-19 pandemic,caused by SARS-CoV-2,continues to rage in many countries,straining health systems and economies.Vaccines protect against severe disease and death and are considered central to ending the pandemic...The COVID-19 pandemic,caused by SARS-CoV-2,continues to rage in many countries,straining health systems and economies.Vaccines protect against severe disease and death and are considered central to ending the pandemic.COVID-19 vaccines(and SARS-CoV-2 infection)elicit antibodies that are directed against the viral spike(S)protein and neutralize the virus.However,the emergence of SARS-CoV-2 variants with S protein mutations that confer resistance to neutralization might compromise vaccine efficacy[1].展开更多
基金SP acknowledges funding by the EU project UNDINE(grant agreement number 101057100)the Ministry for Science and Culture of Lower Saxony(Niedersächsisches Ministerium für Wissenschaft und Kultur,14-76103-184,COFONI Network,including projects 7FF22,6FF22,10FF22)+4 种基金the German Research Foundation(Deutsche Forschungsgemeinschaft,DFG,PO 716/11-1)H-MJ received funding from BMBF(01KI2043,NaFoUniMedCovid19-COVIM:01KX2021)Bavarian State Ministry for Science and the Arts(Bayerisches Staatsministerium für Wissenschaft und Kunst)and DFG through the research training groups RTG1660 and TRR130,the Bayerische Forschungsstiftung(Project CORAd)and the Kastner Foundation.GMNB acknowledges funding by the German Centre for Infection Research(Deutsches Zentrum für Infektionsforschung,DZIFgrant no 80018019238)Further,GMNB and AD-J acknowledge funding by a European Regional Development Fund(Defeat Corona,ZW7-8515131).
文摘Despite previous circulation of the highly transmissible and antibody evasive BA.2.75, BQ.1, XBB.1 and XBB.1.5 lineages, the share of infections caused by the SARS-CoV-2 lineage XBB.1.16 has gradually increased in India in early 2023, resulting in XBB.1.16 being the dominating SARS-CoV-2 lineage in India today. Since a similar trend may also take place in other countries and information on the biological properties of the XBB.1.16 lineage is scarce, we conducted a rapid assessment of the SARS-CoV-2 XBB.1.16 lineage with respect to its ability to enter cells and evade neutralisation by antibodies.
基金SP acknowledges funding by BMBF(01KI2006D,01KI20328A,01KI20396,and 01KX2021)the Ministry for Science and Culture of Lower Saxony(14-76103-184,MWK HZI COVID-19)and the German Research Foundation(DFG,PO 716/11-1,PO 716/14-1)+1 种基金MSW received unrestricted funding from Sartorius AG,Lung Research.HMJ received funding from BMBF(01KI2043,NaFoUniMedCovid19-COVIM:01KX2021)Bavarian State Ministry for Science and the Arts and Deutsche Forschungsgemeinschaft(DFG)through the research training groups RTG1660 and TRR130.G.B.acknowledges funding from the German Center for Infection Research(grant no 80018019238).
文摘The emergence of SARS-CoV-2 variants threatens efforts to control the COVID-19 pandemic.At present,the global spread of the Delta(B.1.617.2)variant is responsible for a rapid increase in COVID-19 cases and hospitalizations in many countries.The variant evades neutralizing antibodies and is believed to be more transmissible and pathogenic[1,2,3,4].
基金S.P.acknowledges funding by BMBF(01KI2006D,01KI20328A,01KI20396,01KX2021)the Ministry for Science and Culture of Lower Saxony(14-76103-184,MWK HZI COVID-19)+2 种基金the German Research Foundation(DFG,PO 716/11-1,PO 716/14-1)M.S.W.received unrestricted funding from Sartorius AG,Lung Research.H.-M.J.received funding from BMBF(01KI2043,NaFoUniMedCovid19-COVIM:01KX2021)Bavarian State Ministry for Science and the Arts and Deutsche Forschungsgemeinschaft(DFG)through the research training groups RTG1660 and TRR130.G.B.acknowledges funding from the German Center for Infection Research(grant no 80018019238).
文摘The COVID-19 pandemic,caused by SARS-CoV-2,continues to rage in many countries,straining health systems and economies.Vaccines protect against severe disease and death and are considered central to ending the pandemic.COVID-19 vaccines(and SARS-CoV-2 infection)elicit antibodies that are directed against the viral spike(S)protein and neutralize the virus.However,the emergence of SARS-CoV-2 variants with S protein mutations that confer resistance to neutralization might compromise vaccine efficacy[1].
